Switch from adalimumab to brodalumab as a possible trigger factor for the onset of pyoderma gangrenosum
Australas J Dermatol. 2024 Apr 10. doi: 10.1111/ajd.14266. Online ahead of print.
NO ABSTRACT
PMID:38597123 | DOI:10.1111/ajd.14266
Von Automat